Regeneron Pharmaceuticals, Inc. Revenue & Financials

The most surprising financial fact about Regeneron is that its reported 2024 collaboration profit from Dupixent was actually $603.7 million lower than the underlying economic profit from the drug — because the company records a contingent reimbursement obligation to Sanofi for development expenses incurred on commercialized antibodies. Strip that accounting adjustment out, and the economic profit from Dupixent and Kevzara alone was $4.53 billion in 2024. Total revenue grew from $13.1 billion in 2023 to $14.2 billion in 2024 to $14.3 billion in 2025. The flattening between 2024 and 2025 reflects the EYLEA dynamic: US net product sales for that drug were favorably impacted by approximately $85 million in Q4 2024 due to higher wholesaler inventory levels — a channel dynamic management explicitly flagged as non-recurring that would reverse in subsequent periods. The underlying patient demand trajectory for EYLEA is being pressured by biosimilar competition. Net income of $4.4 billion in fiscal 2025 on $14.3 billion in revenue produces a 31 percent net margin — high for pharmaceutical companies, achievable here because Dupixent's commercial scale provides the cash flow to fund $5.9 billion in annual R&D while still delivering returns to shareholders. That R&D ratio of 41 percent is the most important number in Regeneron's financials: it represents a bet that the next generation of products from the pipeline will maintain the revenue base when Dupixent eventually faces competition. The Bayer collaboration structure for EYLEA outside the US has remained stable at exactly 39 percent of profits for Regeneron across three consecutive years (2022 through 2024), demonstrating the contractual durability of this arrangement despite currency fluctuations and ex-US sales growth.